{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T21:25:46Z","timestamp":1776979546955,"version":"3.51.4"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,15]],"date-time":"2022-06-15T00:00:00Z","timestamp":1655251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,15]],"date-time":"2022-06-15T00:00:00Z","timestamp":1655251200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["26293123, 22591090, 15K09543, 18K08402"],"award-info":[{"award-number":["26293123, 22591090, 15K09543, 18K08402"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Hospital Organization"},{"DOI":"10.13039\/501100005928","name":"Daiwa Securities Health Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005928","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008728","name":"Japan Research Foundation for Clinical Pharmacology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008728","id-type":"DOI","asserted-by":"publisher"}]},{"name":"The Nakatomi Foundation"},{"DOI":"10.13039\/100007449","name":"Takeda Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007449","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008734","name":"Mitsui Sumitomo Insurance Welfare Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008734","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb Co.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the Ministry of Health, Labour, and Welfare of Japan"},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009015","name":"Abbott Japan Co., Ltd.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100009015","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004324","name":"Astellas Pharma Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Chugai Pharmaceutical Co., Ltd."},{"DOI":"10.13039\/501100023368","name":"Eisai Co., Ltd.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100023368","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100012351","name":"Mitsubishi Tanabe Pharma Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012351","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Merck Sharp and Dohme Inc."},{"name":"Pfizer Japan Inc."},{"name":"Takeda Pharmaceutical Company Limited"},{"name":"Teijin Pharma Limited"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Mixed connective tissue disease (MCTD) is a rare systemic autoimmune disease characterized by the production of anti-U1 ribonucleoprotein antibodies and systemic symptoms similar to those of some other autoimmune diseases. <jats:italic>HLA-DRB1<\/jats:italic> polymorphisms are important genetic risk factors for MCTD, but precise associations of <jats:italic>DRB1<\/jats:italic> genotypes with MCTD have not been reported in Japanese people. Genotyping of <jats:italic>HLA-DRB1<\/jats:italic> and <jats:italic>-DQB1<\/jats:italic> was performed in Japanese MCTD patients (n\u2009=\u2009116) and controls (n\u2009=\u2009413). Associations of specific allele carriers and genotype frequencies with MCTD were analyzed.The following alleles were found to be associated with predisposition to MCTD: <jats:italic>HLA-DRB1*04:01<\/jats:italic> (<jats:italic>P<\/jats:italic>\u2009=\u20098.66\u2009\u00d7\u200910<jats:sup>\u20136<\/jats:sup>, <jats:italic>Pc<\/jats:italic>\u2009=\u20090.0003, odds ratio [OR] 7.96, 95% confidence interval [CI] 3.13\u201220.24) and <jats:italic>DRB1*09:01<\/jats:italic> (<jats:italic>P<\/jats:italic>\u2009=\u20090.0189, <jats:italic>Pc<\/jats:italic>\u2009=\u20090.5468, OR 1.73, 95% CI 1.12\u20122.67). In contrast, the carrier frequency of the <jats:italic>DRB1*13:02<\/jats:italic> allele (<jats:italic>P<\/jats:italic>\u2009=\u20090.0032, <jats:italic>Pc<\/jats:italic>\u2009=\u20090.0929, OR 0.28, 95% CI 0.11\u20120.72) was lower in MCTD patients than in controls. The frequencies of heterozygosity for <jats:italic>HLA-DRB1*04:01\/*15<\/jats:italic> (<jats:italic>P<\/jats:italic>\u2009=\u20091.88\u2009\u00d7\u200910<jats:sup>\u20137<\/jats:sup>, OR 81.54, 95% CI 4.74\u20121402.63) and <jats:italic>DRB1*09:01\/*15<\/jats:italic> (<jats:italic>P<\/jats:italic>\u2009=\u20090.0061, OR 2.94, 95% CI 1.38\u20126.25) were also higher in MCTD patients. Haplotype and logistic regression analyses suggested a predisposing role for <jats:italic>HLA-DRB1*04:01, DQB1*03:03,<\/jats:italic> and a protective role for <jats:italic>DRB1*13:02.<\/jats:italic> Increased frequencies of <jats:italic>HLA-DRB1*04:01\/*15<\/jats:italic> and <jats:italic>DRB1*09:01\/*15<\/jats:italic> heterozygous genotypes were found in Japanese MCTD patients.<\/jats:p>","DOI":"10.1038\/s41598-022-14116-x","type":"journal-article","created":{"date-parts":[[2022,6,15]],"date-time":"2022-06-15T10:03:06Z","timestamp":1655287386000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Predisposition of HLA-DRB1*04:01\/*15 heterozygous genotypes to Japanese mixed connective tissue disease"],"prefix":"10.1038","volume":"12","author":[{"given":"Shomi","family":"Oka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Higuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Furukawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kota","family":"Shimada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akiko","family":"Komiya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshihiro","family":"Matsui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoshi","family":"Fukui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eiichi","family":"Suematsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeru","family":"Ohno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hajime","family":"Kono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masao","family":"Katayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shouhei","family":"Nagaoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyoshi","family":"Migita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeto","family":"Tohma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,6,15]]},"reference":[{"key":"14116_CR1","doi-asserted-by":"publisher","first-page":"386","DOI":"10.2169\/internalmedicine.38.386","volume":"38","author":"R Kasukawa","year":"1999","unstructured":"Kasukawa, R. Mixed connective tissue disease. Intern. Med. 38, 386\u2013393 (1999).","journal-title":"Intern. Med."},{"key":"14116_CR2","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.berh.2016.03.002","volume":"30","author":"R Gunnarsson","year":"2016","unstructured":"Gunnarsson, R., Hetlevik, S. O., Lilleby, V. & Molberg, \u00d8. Mixed connective tissue disease. Best. Pract. Res. Clin. Rheumatol. 30, 95\u2013111 (2016).","journal-title":"Best. Pract. Res. Clin. Rheumatol."},{"key":"14116_CR3","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s10238-020-00606-7","volume":"20","author":"MR Alves","year":"2020","unstructured":"Alves, M. R. & Isenberg, D. A. \u201cMixed connective tissue disease\u201d: A condition in search of an identity. Clin. Exp. Med. 20, 159\u2013166 (2020).","journal-title":"Clin. Exp. Med."},{"key":"14116_CR4","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1136\/ard.2010.143792","volume":"70","author":"R Gunnarsson","year":"2011","unstructured":"Gunnarsson, R., Molberg, O., Gilboe, I. M. & Gran, J. T. The prevalence and incidence of mixed connective tissue disease: A national multicentre survey of Norwegian patients. Ann. Rheum. Dis. 70, 1047\u20131051 (2011).","journal-title":"Ann. Rheum. Dis."},{"key":"14116_CR5","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/0002-9343(72)90064-2","volume":"52","author":"GC Sharp","year":"1972","unstructured":"Sharp, G. C., Irvin, W. S., Tan, E. M., Gould, R. G. & Holman, H. R. Mixed connective tissue disease\u2013an apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA). Am. J. Med. 52, 148\u2013159 (1972).","journal-title":"Am. J. Med."},{"key":"14116_CR6","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1056\/NEJM197611182952112","volume":"295","author":"M Reichlin","year":"1976","unstructured":"Reichlin, M. Problems in differentiating SLE and mixed connective-tissue disease. N. Engl. J. Med. 295, 1194\u20131195 (1976).","journal-title":"N. Engl. J. Med."},{"key":"14116_CR7","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/0049-0172(80)90013-X","volume":"10","author":"RM Bennett","year":"1980","unstructured":"Bennett, R. M. & O\u2019Connell, D. J. Mixed connective tisssue disease: a clinicopathologic study of 20 cases. Semin. Arthritis Rheum. 10, 25\u201351 (1980).","journal-title":"Semin. Arthritis Rheum."},{"key":"14116_CR8","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1002\/art.1780230312","volume":"23","author":"EC LeRoy","year":"1980","unstructured":"LeRoy, E. C., Maricq, H. R. & Kahaleh, M. B. Undifferentiated connective tissue syndromes. Arthritis Rheum. 23, 341\u2013343 (1980).","journal-title":"Arthritis Rheum."},{"key":"14116_CR9","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.rdc.2005.04.007","volume":"31","author":"M Aringer","year":"2005","unstructured":"Aringer, M., Steiner, G. & Smolen, J. S. Does mixed connective tissue disease exist? Yes. Rheum. Dis. Clin. North Am. 31, 411\u2013420 (2005).","journal-title":"Rheum. Dis. Clin. North Am."},{"key":"14116_CR10","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.rdc.2005.04.009","volume":"31","author":"J Swanton","year":"2005","unstructured":"Swanton, J. & Isenberg, D. Mixed connective tissue disease: still crazy after all these years. Rheum. Dis. Clin. North Am. 31, 421\u2013436 (2005).","journal-title":"Rheum. Dis. Clin. North Am."},{"key":"14116_CR11","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1136\/ard.46.3.189","volume":"46","author":"E Genth","year":"1987","unstructured":"Genth, E., Zarnowski, H., Mierau, R., Wohltmann, D. & Hartl, P. W. HLA-DR4 and Gm(1,3;5,21) are associated with U1-nRNP antibody positive connective tissue disease. Ann. Rheum. Dis. 46, 189\u2013196 (1987).","journal-title":"Ann. Rheum. Dis."},{"key":"14116_CR12","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1002\/art.1780310119","volume":"31","author":"CM Black","year":"1988","unstructured":"Black, C. M. et al. HLA and immunoglobulin allotypes in mixed connective tissue disease. Arthritis Rheum. 31, 131\u2013134 (1988).","journal-title":"Arthritis Rheum."},{"key":"14116_CR13","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1136\/ard.51.1.52","volume":"51","author":"P Ruuska","year":"1992","unstructured":"Ruuska, P. et al. Differences in HLA antigens between patients with mixed connective tissue disease and systemic lupus erythematosus. Ann. Rheum. Dis. 51, 52\u201355 (1992).","journal-title":"Ann. Rheum. Dis."},{"key":"14116_CR14","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1002\/art.1780380216","volume":"38","author":"NS Gendi","year":"1995","unstructured":"Gendi, N. S. et al. HLA type as a predictor of mixed connective tissue disease differentiation. Ten-year clinical and immunogenetic followup of 46 patients. Arthritis Rheum. 38, 259\u2013266 (1995).","journal-title":"Arthritis Rheum."},{"key":"14116_CR15","first-page":"91","volume":"17","author":"AL Weckmann","year":"1999","unstructured":"Weckmann, A. L. et al. Immunogenetics of mixed connective tissue disease in a Mexican Mestizo population. Clin. Exp. Rheumatol. 17, 91\u201394 (1999).","journal-title":"Clin. Exp. Rheumatol."},{"key":"14116_CR16","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/S0198-8859(02)00776-0","volume":"64","author":"AB Hassan","year":"2003","unstructured":"Hassan, A. B. et al. MICA4\/HLA-DRB1*04\/TNF1 haplotype is associated with mixed connective tissue disease in Swedish patients. Hum. Immunol. 64, 290\u2013296 (2003).","journal-title":"Hum. Immunol."},{"key":"14116_CR17","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1111\/tan.12698","volume":"87","author":"A Paradowska-Gorycka","year":"2015","unstructured":"Paradowska-Gorycka, A. et al. Association of HLA-DRB1 alleles with susceptibility to mixed connective tissue disease in Polish patients. Hla 87, 13\u201318 (2015).","journal-title":"Hla"},{"key":"14116_CR18","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1093\/rheumatology\/keu310","volume":"54","author":"ST Fl\u00e5m","year":"2015","unstructured":"Fl\u00e5m, S. T., Gunnarsson, R., Garen, T., Lie, B. A. & Molberg, \u00d8. The HLA profiles of mixed connective tissue disease differ distinctly from the profiles of clinically related connective tissue diseases. Rheumatology (Oxford) 54, 528\u2013535 (2015).","journal-title":"Rheumatology (Oxford)"},{"key":"14116_CR19","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/j.1399-0039.1993.tb01972.x","volume":"41","author":"RP Dong","year":"1993","unstructured":"Dong, R. P. et al. Difference in HLA-linked genetic background between mixed connective tissue disease and systemic lupus erythematosus. Tissue Antigens 41, 20\u201325 (1993).","journal-title":"Tissue Antigens"},{"key":"14116_CR20","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1111\/tan.12027","volume":"81","author":"K Yoshida","year":"2013","unstructured":"Yoshida, K. et al. Mixed connective tissue disease is distinct from systemic lupus erythematosus: Study of major histocompatibility complex class I polypeptide-related sequence A and HLA gene polymorphisms. Tissue Antigens 81, 44\u201345 (2013).","journal-title":"Tissue Antigens"},{"key":"14116_CR21","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1136\/ard.46.6.457","volume":"46","author":"JS Smolen","year":"1987","unstructured":"Smolen, J. S. et al. HLA-DR antigens in systemic lupus erythematosus: Association with specificity of autoantibody responses to nuclear antigens. Ann. Rheum. Dis. 46, 457\u2013462 (1987).","journal-title":"Ann. Rheum. Dis."},{"key":"14116_CR22","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1002\/art.1780381218","volume":"38","author":"RW Hoffman","year":"1995","unstructured":"Hoffman, R. W., Sharp, G. C. & Deutscher, S. L. Analysis of anti-U1 RNA antibodies in patients with connective tissue disease. Association with HLA and clinical manifestations of disease. Arthritis Rheum. 38, 1837\u20131844 (1995).","journal-title":"Arthritis Rheum."},{"key":"14116_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/gene.2016.40","volume":"18","author":"H Furukawa","year":"2017","unstructured":"Furukawa, H. et al. The role of common protective alleles HLA-DRB1*13 among systemic autoimmune diseases. Genes Immun. 18, 1\u20137 (2017).","journal-title":"Genes Immun."},{"key":"14116_CR24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0087792","volume":"9","author":"H Furukawa","year":"2014","unstructured":"Furukawa, H. et al. Human leukocyte antigens and systemic lupus erythematosus: A protective role for the HLA-DR6 alleles DRB1*13:02 and *14:03. PLoS ONE 9, e87792 (2014).","journal-title":"PLoS ONE"},{"key":"14116_CR25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0154255","volume":"11","author":"H Furukawa","year":"2016","unstructured":"Furukawa, H. et al. Human Leukocyte Antigen and Systemic Sclerosis in Japanese: The Sign of the Four Independent Protective Alleles, DRB1*13:02, DRB1*14:06, DQB1*03:01, and DPB1*02:01. PLoS ONE 11, e0154255 (2016).","journal-title":"PLoS ONE"},{"key":"14116_CR26","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1080\/14397595.2019.1637593","volume":"30","author":"H Furukawa","year":"2020","unstructured":"Furukawa, H. et al. Human leukocyte antigen in Japanese patients with idiopathic inflammatory myopathy. Mod. Rheumatol. 30, 696\u2013702 (2020).","journal-title":"Mod. Rheumatol."},{"key":"14116_CR27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0099453","volume":"9","author":"S Oka","year":"2014","unstructured":"Oka, S. et al. Protective effect of the HLA-DRB1*13:02 allele in Japanese rheumatoid arthritis patients. PLoS ONE 9, e99453 (2014).","journal-title":"PLoS ONE"},{"key":"14116_CR28","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.2337\/db07-1331","volume":"57","author":"H Erlich","year":"2008","unstructured":"Erlich, H. et al. HLA DR-DQ haplotypes and genotypes and type 1 diabetes risk: Analysis of the type 1 diabetes genetics consortium families. Diabetes 57, 1084\u20131092 (2008).","journal-title":"Diabetes"},{"key":"14116_CR29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0187325","volume":"12","author":"S Oka","year":"2017","unstructured":"Oka, S. et al. HLA-DRB1 and DQB1 alleles in Japanese type 1 autoimmune hepatitis: The predisposing role of the DR4\/DR8 heterozygous genotype. PLoS ONE 12, e0187325 (2017).","journal-title":"PLoS ONE"},{"key":"14116_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.12667\/mhc.8.1","volume":"8","author":"F Nakajima","year":"2001","unstructured":"Nakajima, F., Nakamura, J. & Yokota, T. Analysis of HLA haplotypes in Japanese, using high resolution allele typing. MHC 8, 1\u201332 (2001).","journal-title":"MHC"},{"key":"14116_CR31","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1038\/jhg.2015.23","volume":"60","author":"S Kamitsuji","year":"2015","unstructured":"Kamitsuji, S. et al. Japan PGx Data Science Consortium Database: SNPs and HLA genotype data from 2994 Japanese healthy individuals for pharmacogenomics studies. J. Hum. Genet. 60, 319\u2013326 (2015).","journal-title":"J. Hum. Genet."},{"key":"14116_CR32","first-page":"71","volume":"23","author":"N Kamatani","year":"2004","unstructured":"Kamatani, N. et al. Establishment of B-cell lines derived from 996 Japanese individuals. Tissue Culture Res. Commun. 23, 71\u201380 (2004).","journal-title":"Tissue Culture Res. Commun."},{"key":"14116_CR33","first-page":"41","volume-title":"Mixed connective tissue disease and anti-nuclear antibodies: proceedings of the International Symposium on Mixed Connective Tissue Disease and Anti-nuclear Antibodies","author":"RT Kasukawa","year":"1987","unstructured":"Kasukawa, R. T., Miyawaki, T., Yoshida, S., Tanimoto, H. & Nobunaga, K. In Mixed connective tissue disease and anti-nuclear antibodies: proceedings of the International Symposium on Mixed Connective Tissue Disease and Anti-nuclear Antibodies (eds Sharp, G. C. & Kasukawa, R.) 41\u201347 (Elsevier Science Publishers, Berlin, 1987)."},{"key":"14116_CR34","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.2169\/naika.101.1413","volume":"101","author":"SFS Yoshida","year":"2012","unstructured":"Yoshida, S. F. S. The Cutting-edge of Medicine: Progress in the diagnosis and treatment of mixed connective tissue disease. J. Japan. Soc. Internal Med. 101, 1413\u20131419 (2012).","journal-title":"J. Japan. Soc. Internal Med."},{"key":"14116_CR35","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1080\/14397595.2019.1709944","volume":"31","author":"Y Tanaka","year":"2021","unstructured":"Tanaka, Y. et al. 2019 Diagnostic criteria for mixed connective tissue disease (MCTD): From the Japan research committee of the ministry of health, labor, and welfare for systemic autoimmune diseases. Mod Rheumatol 31, 29\u201333 (2021).","journal-title":"Mod Rheumatol"},{"key":"14116_CR36","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1111\/j.1471-8286.2007.01931.x","volume":"8","author":"F Rousset","year":"2008","unstructured":"Rousset, F. genepop\u2019007: A complete re-implementation of the genepop software for Windows and Linux. Mol Ecol Resour 8, 103\u2013106 (2008).","journal-title":"Mol Ecol Resour"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-14116-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-14116-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-14116-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T05:18:40Z","timestamp":1669353520000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-14116-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,15]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["14116"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-14116-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,15]]},"assertion":[{"value":"22 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"HF has the following conflicts, and the following funders are supported wholly or in part by the indicated pharmaceutical companies. The Japan Research Foundation for Clinical Pharmacology is run by Daiichi Sankyo, the Takeda Science Foundation is supported by an endowment from the Takeda Pharmaceutical Company, and the Nakatomi Foundation was established by Hisamitsu Pharmaceutical Co., Inc. The Daiwa Securities Health Foundation was established by Daiwa Securities Group Inc. and Mitsui Sumitomo Insurance Welfare Foundation was established by Mitsui Sumitomo Insurance Co., Ltd. HF was supported by research grants from Bristol-Myers Squibb Co. HF received honoraria from Ajinomoto Co., Inc., Daiichi Sankyo Co., Ltd., Dainippon Sumitomo Pharma Co., Ltd., Pfizer Japan Inc., Takeda Pharmaceutical Company, Luminex Japan Corporation Ltd., and Ayumi Pharmaceutical Corporation. ST was supported by research grants from nine pharmaceutical companies: Abbott Japan Co., Ltd., Astellas Pharma Inc., Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Merck Sharp and Dohme Inc., Pfizer Japan Inc., Takeda Pharmaceutical Company Limited, and Teijin Pharma Limited. ST received honoraria from Asahi Kasei Pharma Corporation, Astellas Pharma Inc., AbbVie GK., Chugai Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Corporation, and Pfizer Japan Inc. The other authors declare no financial or commercial conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9916"}}